Fulgent Genetics, Inc. (FLGT) financial statements (2020 and earlier)

Company profile

Business Address 4978 SANTA ANITA AVENUE, SUITE 205
TEMPLE CITY, CA 91780
State of Incorp. DE
Fiscal Year End December 31
SIC 8071 - Medical Laboratories (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments28312621
Cash and cash equivalents12768
Short-term investments16242013
Receivables7644
Other current assets2321
Total current assets:37403326
Noncurrent Assets
Operating lease, right-of-use asset3
Property, plant and equipment6676
Long-term investments and receivables4381726
Long-term investments4381726
Other noncurrent assets0000
Deferred tax assets, net 0 
Other undisclosed noncurrent assets   0
Total noncurrent assets:52142432
TOTAL ASSETS:89545758
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3333
Accounts payable2123
Accrued liabilities1110
Taxes payable0  0
Deferred revenue0
Debt0   
Total current liabilities:4333
Noncurrent Liabilities
Long-term debt and lease obligation2   
Operating lease, liability2
Liabilities, other than long-term debt 000
Deferred tax liabilities, net  0
Other liabilities 000
Total noncurrent liabilities:2000
Total liabilities:6334
Stockholders' equity
Stockholders' equity attributable to parent83515454
Common stock0000
Additional paid in capital146114112110
Accumulated other comprehensive income (loss)0(0)(0)(0)
Accumulated deficit(63)(63)(58)(55)
Total stockholders' equity:83515454
TOTAL LIABILITIES AND EQUITY:89545758

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues33211918
Cost of revenue(14)(11)(9)(7)
Gross profit:18111012
Operating expenses(19)(16)(14)(11)
Operating income (loss):(0)(5)(3)1
Other undisclosed income from continuing operations before equity method investments, income taxes100 
Income (loss) from continuing operations before equity method investments, income taxes:0(5)(3)1
Loss from equity method investments(1)(1)(1) 
Other undisclosed loss from continuing operations before income taxes   (5)
Loss from continuing operations before income taxes:(0)(6)(4)(4)
Income tax expense (benefit)(0)(0)1(1)
Loss from continuing operations:(0)(6)(3)(5)
Income from discontinued operations   0
Net loss attributable to parent:(0)(6)(3)(5)
Other undisclosed net loss available to common stockholders, basic   (8)
Net loss available to common stockholders, diluted:(0)(6)(3)(14)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(0)(6)(3)(5)
Other comprehensive income (loss)000(0)
Comprehensive loss, net of tax, attributable to parent:(0)(6)(2)(5)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: